本季度信息
2025年第三季度，北京昭衍新药研究中心股份有限公司实现营收3.16亿元（人民币，下同），较上年同期下降34.87%。同期经调整净利润（扣除非经常性损益后）为599.26万元，同比下降92.94%。公告显示，公司本季度业绩受市场竞争加剧、订单价格下滑等因素影响，导致实验室服务业务利润空间进一步收窄。
从成本结构来看，2025年1–9月销售费用约占营业收入的2.24%，管理费用约占21.68%，研发投入约占6.49%。同期经营活动产生的现金流量净额达2.66亿元，较去年同期增长38.51%，显示公司在成本管控方面仍保持一定的资金流转效率。
业务分项
公告提及，公司主要收入来源于实验室服务与生物资产公允价值变动收益等。前者在市场竞争环境下，盈利能力受到挤压；而生物资产公允价值变动收益在今年前三季度对公司净利润产生正面贡献，弥补部分实验室服务利润下滑的影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.